WO2004075881A1 - Stable pharmaceutical composition of rabeprazole and processes for their preparation - Google Patents

Stable pharmaceutical composition of rabeprazole and processes for their preparation Download PDF

Info

Publication number
WO2004075881A1
WO2004075881A1 PCT/IB2004/000536 IB2004000536W WO2004075881A1 WO 2004075881 A1 WO2004075881 A1 WO 2004075881A1 IB 2004000536 W IB2004000536 W IB 2004000536W WO 2004075881 A1 WO2004075881 A1 WO 2004075881A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
core
pharmaceutical composition
stable pharmaceutical
composition according
rabeprazole
Prior art date
Application number
PCT/IB2004/000536
Other languages
French (fr)
Inventor
Romi Barat Singh
Pananchukunnath Manoj Kumar
Vishnubhotla Nagaprasad
Rajiv Malik
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

The invention relates to stable pharmaceutical compositions of rabeprazole and processes for their preparation. The stable pharmaceutical composition includes a core and the core includes rabeprazole and at least 10 % w/w of low viscosity hydroxypropylcellulose.

Description

STABLE PHARMACEUTICAL COMPOSITION OF RABEPRAZOLE AND PROCESSES FOR THEIR PREPARATION

Field of the Invention

The technical field of the present invention relates to stable pharmaceutical compositions of rabeprazole, and processes for their preparation.

Background of the Invention

2 - [[[4 - (3-methoxypropoxy) - 3 - methyl - 2-pyridinyl] - methyl] sulfinyl] - 1H - benzimidazole, hereinafter referred to as rabeprazole, belongs to the class of H+ - K+ - ATPase inhibitors. Its intense effect of suppressing gastric acid secretion, and an appropriate duration of action, makes it useful for treatment of various digestive ulcers.

Rabeprazole, however, is prone to rapid decomposition and discoloration in the presence of moisture at neutral to acidic conditions. Conventional stabilizing measures of coating acid sensitive compounds with enteric polymers are unsuitable for rabeprazole because the acidic functional groups of the enteric polymer react with rabeprazole, leading to its decomposition. A subcoating to separate the core and enteric coat is used but decomposition of the rabeprazole nonetheless occurs during the coating stage when the rabeprazole is in contact with coating compositions in commonly used coating equipment, such as fluidized bed coaters. Consequently, other approaches have been attempted to stabilize rabeprazole in pharmaceutical compositions. For example, U.S. Patent No. 5,035,899 discloses a method of stabilizing a core containing an acid unstable compound. The unstable core is stabilized by layering the core with a subcoat layer, followed by layering with an enteric coat layer. The subcoat layer or the intermediate layer includes a water insoluble film forming material and a suspended, water insoluble fine material. U.S. Patent Application No. 2002/0039597 discloses a chemically stable pharmaceutical preparation of a benzimidazole type compound in which the preparation is stabilized by incorporating in the core at least one substance selected from sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, amino alkyl methacrylate copolymer E, arginine aspartate, hydroxypropylcellulose and crospovidone. Summary of the Invention

In one general aspect there is provided a stable pharmaceutical composition that includes a core. The core includes rabeprazole and at least 10% w/w of low viscosity hydroxypropylcellulose. Embodiments of the composition may include one or more of the following features. For example, the core may further include an antioxidant. The antioxidant may be one or both of butylated hydroxy toluene and butylated hydroxy anisole. The antioxidant may be from about 0.02% to about 0.2% by weight of the total core weight.

The viscosity of the low viscosity hydroxypropylcellulose may range from about 5 m. Pas to about 300 m. Pas (i.e., 5 cp to about 300 cp). More particularly, the viscosity of the low viscosity hydroxypropylcellulose may range from about 50 m. Pas to about 200 m. Pas.

The core may further include polyvinylpyrrolidone. The average molecular weight of the polyvinylpyrrolidone may range from about 10,000 to about 360,000. More particularly, the average molecular weight of polyvinylpyrrolidone may range from about 40,000 to about 60,000. The polyvinylpyrrolidone maybe from about 0.5% to about 5% by weight of the total core weight.

The core maybe selected from the group consisting of tablet, granule and capsule and, in particular, may be a tablet. The core may be coated with a subcoat layer and an enteric coat layer. The subcoat layer may be one or more film forming agents. The one or more film forming agents maybe one or more of microcrystalline cellulose, carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum and, in particular, maybe hydroxypropyl methylcellulose.

The subcoat layer may include an antioxidant. The enteric coat layer may include one or more enteric polymers. The enteric polymer may be one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers and, in particular, may be hydroxypropyl methylcellulose phthalate. One or more of the core, the subcoat layer, and the enteric layer may further include one or more pharmaceutically acceptable inert excipients. The one or more pharmaceutically acceptable inert excipients may be selected from the group consisting of binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents.

In another general aspect there is provided a process for preparing a stable pharmaceutical composition that includes a core. The process includes preparing a core by (i) blending rabeprazole and a low viscosity hydroxypropylcellulose to form a blend, and, one or both of, (ii) granulating the blend and (iii) compressing the blend to form a compact mass core. The low viscosity hydroxypropylcellulose makes up at least 10% w/w of the core.

Embodiments of the process may include one or more of the following features. For example, the viscosity of the low viscosity hydroxypropylcellulose may range from about 5 m. Pas to about 300 m. Pas. The process may further include blending one or more antioxidants with the rabeprazole and low viscosity hydroxypropylcellulose. The antioxidant may be adsorbed over a diluent.

The core may be selected from the group consisting of tablet, granule and pellet and, in particular, may be a tablet. The core may be prepared by one or more of a wet granulation method, a dry granulation method, or a direct compression method and, in particular, the core may be prepared by direct compression method.

The process may further include coating the core with one or both of a subcoat layer and an enteric coat layer. One or both of the subcoat layer and the enteric coat layer may be applied as a solution suspension. The solution/suspension may be prepared in solvents selected from the group consisting of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof. Alternatively, one or both of the subcoat layer and the enteric coat layer are applied using a hot melt technique.

One or more of the core, the subcoat layer, and the enteric coat layer may contain one or more pharmaceutically acceptable inert excipients.

The one or more pharmaceutically acceptable inert excipients may be selected from the group consisting of binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents. In another general aspect there is provided a method of treating digestive ulcers in a mammal by administering to the mammal a stable pharmaceutical composition of rabeprazole. The composition includes a core that includes rabeprazole and at least 10% w/w of low viscosity hydroxypropyl cellulose. Embodiments of the method may include one or more of the following features and those described above. For example, the viscosity of the low viscosity hydroxypropylcellulose may range from about 5 m. Pas to about 300 m. Pas. The core may further include an antioxidant.

The details of one or more embodiments of the inventions are set forth in the description below. Other features and advantages of the inventions will be apparent from the description and the claims.

Detailed Description of the Invention

We have discovered that a core containing rabeprazole may be stabilized against decomposition by incorporating a stabilizing amount of low viscosity hydroxypropylcellulose (HPC-L) alone or in combination with one or more antioxidants in the core. When used alone, an HPC-L concentration of 10% w/w or more gave improved stability results, as evident below in Table 2.

The use of HPC-L has proved to be useful in preventing the decomposition and discoloration of compositions containing rabeprazole at a concentration of 10% w/w or more of the core. Combining one or more antioxidants with HPC-L helps to improve stability and allows a reduction of HPC-L in the core to an amount of less than 10% w/w. Similarly, incorporating polyvinylpyrrolidone (PVP) in the core has a positive effect on the stability of rabeprazole. Moreover, there is improved stability even with the addition of PVP and a reduction in HPC-L below 10% (w/w). As described in more detail below, these positive effects are evident from the stability data that has been generated over a period of 1 month at 60°C and is contained herein in Tables 1 and 2.

The term "rabeprazole" as used herein includes rabeprazole and its pharmaceutically acceptable salts thereof. The pharmaceutically acceptable salts include salts of rabeprazole with alkali metals such as sodium, potassium, calcium, magnesium and the like. In particular, rabeprazole sodium or rabeprazole potassium may be used. The term "stable" as used herein refers to chemical stability of rabeprazole in pharmaceutical compositions and indicates a presence of at least 80%> w/w of rabeprazole when stored at 60° C for 1 month with respect to the initial amount of rabeprazole as measured, for example, by HPLC. The term "core" as used herein refers to a compact mass having a definite geometric shape such as tablets, granules, pellets and the like; comprising rabeprazole, HPC-L and, optionally, one or more antioxidants. The core may also contain polyvinylpyrrolidione and other pharmaceutically inert excipients. The core may be prepared by any conventional method known in the art such as wet granulation, dry granulation, direct compression, extrusion-spheronization, moldings and the like.

HPC-L is low viscosity hydroxypropylcellulose which is conventionally used as a binder in low concentrations. It is available in various grades under the trade names Klucel® E, Klucel® G, Klucel® J and Klucel® L., with viscosity varying from about 5 m. Pas to about 300 m. Pas. In particular, Klucel® L (having viscosity of 65 - 150 m Pas.) can be used in the pharmaceutical compositions of stabilized rabeprazole described herein. It is noted that 1 m.Pas. is the same as 1 centipoise (cP).

Examples of antioxidants include lipophilic antioxidants, inorganic antioxidants, and the like. In particular, examples of two suitable antioxidants are butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT). The concentration of the one or more antioxidants may vary from about 0.02% to about 0.2% by weight of the total weight of the core. Although the one or more antioxidants are generally incorporated in the core, optionally, the subcoat may also or instead contain the one or more antioxidant(s) at concentrations of about 0.02% to about 0.5% of the weight of the subcoat.

Polyvinylpyrrolidone (PVP) is a water-soluble polymer that is conventionally used as a binder. The average molecular weight of polyvinylpyrrolidone may vary from about 10,000 to about 360,000. It is commercially available in five viscosity grades identified by their K-value: K-15, K-25, K-30, K-60 and K-90, according to viscosity in ascending order. Polyvinylpyrrolidone K 30 (average molecular weight of 58,000) is particularly useful. The concentration of PVP may vary from about 0.5% to about 5.0% by weight of the total weight of core. The term "pharmaceutically inert excipients" as used herein includes binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, coloring agents and the like.

Examples of binders include methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, gelatin, gum Arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol, and the like.

Examples of disintegrants include starch, croscarmellose, crospovidone, sodium starch glycolate and the like.

Examples of lubricants and glidants include colloidal anhydrous silica, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acids, microcrystalline wax, yellow beeswax, white beeswax and the like.

Examples of diluents include calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, silicified microcrystalline cellulose, cellulose powdered, dextrates, dextrins, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sorbitol, starch, starch pregelatinized, sucrose, sugar compressible, sugar confectioners, and the like.

Examples of plasticizers include acetylated triacetin, triethylcitrate, tributylcitrate, glyceroltributyrate, monoglyceride, poly ethylene glycols, propylene glycol, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethyl phthalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, and the like.

Examples of opacifiers include ferric oxide, titanium dioxide and the like.

Examples of coloring agents include any FDA approved colors for oral use.

The subcoat layer comprises a film-forming agent with or without other pharmaceutically inert excipients. Optionally, the subcoat layer may also contain one or more antioxidants. Examples of film forming agents include microcrystalline cellulose, carageenan, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol, xanthan gum and the like. The enteric coat layer includes an enteric polymer with or without other pharmaceutically inert excipients. Examples of enteric polymers include cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate (HPMC phthalate), hydroxypropyl methylcellulose acetate succinate; methacrylic acid copolymers such as Eudragit® L 100-55, Eudragit® L30 D-55, Eudragit® L 100, Eudragit® S 100; and mixtures thereof. A preferred enteric polymer for the purpose of the present invention is HPMC phthalate in a concentration of about 50% to about 90% by weight of the total weight of the enteric coat layer.

As described in greater detail below, in one of the embodiments, there is provided a process for the preparation of a stable tablet of rabeprazole. The process includes preparing a core and coating the core with subcoat and enteric coat layers. Preparing the core includes: (i) blending rabeprazole, HPC-L and, optionally, one or more antioxidants to form a blend, (ii) dry granulating the blend by roller compactor or slugging, (iii) sizing the granules and, optionally, blending with one or more pharmaceutically acceptable inert excipients, and (iv) compressing to form a compact mass. It is this compact mass that is then coated with the subcoat and enteric coat layers.

In another embodiment, there is provided a process for the preparation of a stable tablet of rabeprazole comprising the steps of (a) preparing a core (i) by blending rabeprazole, HPC-L and optionally antioxidant with or without pharmaceutically acceptable inert excipients (ii) forming a wet mass using a granulating fluid or solution dispersion of pharmaceutically acceptable inert excipient in the granulating fluid (iii) drying and lubricating the granules and (iv) compressing to form a compact mass and (b) coating the core with subcoat and enteric coat layers.

In another embodiment, there is provided a process for the preparation of a stable tablet of rabeprazole comprising the steps of (a) preparing a core by (i) blending rabeprazole, HPC-L and optionally antioxidant with or without pharmaceutically acceptable inert excipients (ii) forming a wet mass using a granulating fluid or solution/dispersion of pharmaceutically acceptable inert excipient in the granulating fluid (iii) passing the wet mass through an extruder equipped with a screen; (iv) spheronizing the extrudate in a spheronizer; (v) drying and sizing the spheroids to form a compact mass and (b) coating the core with sub-coat and enteric coat layers.

In another embodiment, there is provided a process for the preparation of a stable tablet of rabeprazole comprising the steps of (a) preparing a core by (i) blending rabeprazole, HPC-L and at least one antioxidant adsorbed over a diluent and (ii) compressing to form a compact mass and (b) coating the core with sub-coat and enteric coat layers.

The sub coat layer and enteric coat layer may be applied over the core as solution/suspension of film forming agent or enteric polymer with or without other pharmaceutically inert excipients using any conventional coating technique known in the prior art such as spray coating in a conventional coating pan or fluidized bed processor; or dip coating.

Alternatively, coating can also be performed using hot melt technique whenever possible.

The solvents used for coating processes or for granulation may be selected from methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.

The invention is further illustrated by the following examples but they should not be construed as limiting the scope of the invention any way.

EXAMPLE 1-8

The core tablet compositions for Examples 1-8 are listed in Table 1. The results of the stability evaluation of core compositions for Examples 1-8 over a period of 1 month at 60°C are listed in Table 2. The preparation of the core tablets of Examples 1-3 involved the following steps:

1. Rabeprazole sodium, mannitol, low substituted-HPC, HPC-L and magnesium oxide were mixed together to form a uniform blend.

2. The blend of step 1 was lubricated by mixing with magnesium stearate.

3. The final lubricated blend of step 2 was directly compressed into core tablets using suitable size punches.

The preparation of the core tablets of Examples 4-8 which incorporates an antioxidant, involved the following steps:

1. BHA and/or BHT was dissolved in isopropyl alcohol, adsorbed over mannitol, and dried in a fluidized bed dryer at room temperature. 2. Rabeprazole sodium, BHA and/or BHT coated mannitol, low substituted-HPC, L- HPC and magnesium oxide were mixed together to form a uniform blend.

3. The blend of step 2 was lubricated by mixing with magnesium stearate.

4. The final lubricated blend of step 3 was directly compressed into core tablets using suitable size punches.

Figure imgf000011_0001

Table 2. Results of stability evaluation of core tablets (Examples 1-8) as percentage (w/w) rabeprazole content, over a period of 1 month at 60°C.

Figure imgf000011_0002

The above core tablets of Examples 1-8 were coated with the sub coat layer and enteric coat layer using the following coating compositions: (i) Sub coat layer

Hydroxypropylmethyl cellulose 26.06 mg

Polyvinyl pyrrolidone 0.53 mg

Titanium dioxide 0.46 mg

Ferric oxide yellow 0.07 mg

Propylene Glycol 3.91 mg

Water. q.s. teric coat layer

HPMC Phthalate 55 13.04 mg

Triacetin 1.46 mg

Talc 4.09 mg

Ferric oxide yellow 0.02 mg

Titanium dioxide 0.72 mg

Acetone q.s.

Procedure:

A. The coating of the core tablets of Examples 1 - 8 with the sub coat layer involved the following steps- 1. Color and titanium dioxide were added in propylene glycol and thoroughly mixed to obtain a homogenous dispersion.

2. Hydroxypropyl methylcellulose and polyvinylpyrrolidone were added in water and mixed thoroughly to obtain a uniform dispersion.

3. The dispersion of step 1 was added to the dispersion of step 2 with stirring to obtain the final sub coat dispersion.

4. Core tablets obtained above were loaded in Freund Hi-Coater and coated with the final dispersion of step 3 until the desired weight build up was achieved, followed by drying if required.

B. The enteric coating of the subcoated tablet involved the following steps- 1. Triacetin was dispersed in part of the acetone followed by the addition of HPMC

Phthalate and continuous stirring until a clear solution was obtained. 2. Color, titanium dioxide and talc were added to the remaining part of the acetone and thoroughly mixed to obtain a uniform dispersion. 3. The dispersion of step 2 was added to the solution of step 1 with continuous stirring to obtain the final coating dispersion.

4. Sub coated tablets were loaded in a Freund Hi-Coater and coated with the final dispersion of step 3 until the desired weight buildup was achieved, followed by drying wherever required.

While several particular forms of the invention have been illustrated and described, it will be apparent that various modifications and combinations of the invention detailed in the text can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

Claims

WE CLAIM: 1. A stable pharmaceutical composition comprising a core, wherein the core includes rabeprazole and at least 10% w/w of low viscosity hydroxypropylcellulose.
2. The stable pharmaceutical composition according to claim 1, wherein the core further comprises an antioxidant.
3. The stable pharmaceutical composition according to claim 1, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.
4. The stable pharmaceutical composition according to claim 3, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 50 m. Pas to about 200 m. Pas.
5. The stable pharmaceutical composition according to claim 2, wherein antioxidant comprises one or both of butylated hydroxy toluene and butylated hydroxy anisole.
6. The stable pharmaceutical composition according to claim 5, wherein the antioxidant comprises from about 0.02% to about 0.2% by weight of the total core weight.
7. The stable pharmaceutical composition according to claim 1, wherein the core further comprise polyvinylpyrrolidone.
8. The stable phaπnaceutical composition according to claim 7, wherein the average molecular weight of the polyvinylpyrrolidone ranges from about 10,000 to about 360,000.
9. The stable pharmaceutical composition according to claim 8, wherein the average molecular weight of polyvinylpyrrolidone ranges from about 40,000 to about 60,000.
10. The stable pharmaceutical composition according to claim 7, wherein the polyvinylpyrrolidone comprises from about 0.5% to about 5% by weight of the total core weight.
11. The stable pharmaceutical composition according to claims 1, wherein the core is selected from the group consisting of tablet, granule and capsule.
12. The stable pharmaceutical composition according to claim 11 wherein the core is a tablet.
13. The stable pharmaceutical composition according to claim 1, wherein the core is coated with a subcoat layer and an enteric coat layer.
14. The stable pharmaceutical composition according to claim 13, wherein the subcoat layer comprises one or more film forming agents.
15. The stable pharmaceutical composition according to claim 14, wherein the one or more film forming agents comprises one or more of microcrystalline cellulose, carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum.
16. The stable pharmaceutical composition according to claim 15, wherein the film-forming agent comprises hydroxypropyl methylcellulose.
17. The stable pharmaceutical composition according to claim 13 wherein the subcoat layer includes an antioxidant.
18. The stable pharmaceutical composition according to claim 13, wherein the enteric coat layer comprises one or more enteric polymers.
19. The stable pharmaceutical composition according to claim 18, wherein the enteric polymer comprises one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers.
20. The stable pharmaceutical composition according to claim 19, wherein the enteric polymer comprises hydroxypropyl methylcellulose phthalate.
21. The stable pharmaceutical composition according to claim 13, wherein one or more of the core, the subcoat layer, and the enteric layer further comprise pharmaceutically acceptable inert excipients.
22. The stable pharmaceutical composition according to claim 21, wherein the one or more pharmaceutically acceptable inert excipients are selected from the group consisting of binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents.
23. A process for preparing a stable pharmaceutical composition comprising a core, the process comprising: preparing a core by (i) blending rabeprazole and a low viscosity hydroxypropylcellulose to form a blend, and one or both of (ii) granulating the blend and (iii) compressing the blend to form a compact mass core, wherein the low viscosity hydroxypropylcellulose comprises at least 10% w/w of the core.
24. The process of claim 23, further comprising coating the core with one or both of a subcoat layer and an enteric coat layer.
25. The process of claim 23, further comprising blending one or more antioxidants with the rabeprazole and low viscosity hydroxypropylcellulose.
26. The process according to claim 25, wherein the antioxidant is adsorbed over a diluent.
27. The process according to claim 23, wherein the core is selected from the group consisting of tablet, granule and pellet.
28. The process according to claim 27, wherein the core comprises a tablet.
29. The process according to claim 23, wherein the core is prepared by one or more of a wet granulation method, a dry granulation method, or a direct compression method.
30. The process according to claim 29, wherein the core is prepared by direct compression method.
31. The process according to claim 24, wherein one or both of the subcoat layer and the enteric coat layer are applied as a solution/suspension.
32. The process according to claim 31, wherein the solution/suspension is prepared in solvents selected from the group consisting of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.
33. The process according to claim 24, wherein one or both of the subcoat layer and the enteric coat layer are applied using a hot melt technique.
34. The process according to claim 24, wherein one or more of the core, the subcoat layer, and the enteric coat layer contains one or more pharmaceutically acceptable - inert excipients.
35. The process according to claim 34, wherein the one or more pharmaceutically acceptable inert excipients is selected from the group consisting of binders, disintegi-ants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents.
36. The process according to claim 24, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.
37. A method of treating digestive ulcers in a mammal by administering to the mammal a stable pharmaceutical composition of rabeprazole, wherein the composition includes a core comprises rabeprazole and at least 10% w/w of low viscosity hydroxypropyl cellulose.
38. The method of treating of claim 37 , wherein the viscosity of the low viscosity hydroxypiOpylcellulose ranges from about 5 m. Pas to about 300 m. Pas.
39. The method of treating of claim 37, wherein the core further comprises an antioxidant.
PCT/IB2004/000536 2003-02-28 2004-03-01 Stable pharmaceutical composition of rabeprazole and processes for their preparation WO2004075881A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN203/DEL/2003 2003-02-28
IN203DE2003 2003-02-28

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20040715973 EP1605919A1 (en) 2003-02-28 2004-03-01 Stable pharmaceutical composition of rabeprazole and processes for their preparation
CA 2517289 CA2517289A1 (en) 2003-02-28 2004-03-01 Stable pharmaceutical composition of rabeprazole and processes for their preparation
EP20040769201 EP1696889A1 (en) 2003-08-28 2004-08-27 Pharmaceutical compositions of benzimidazole and processes for their preparation
PCT/IB2004/002784 WO2005027876A1 (en) 2003-08-28 2004-08-27 Pharmaceutical compositions of benzimidazole and processes for their preparation

Publications (1)

Publication Number Publication Date
WO2004075881A1 true true WO2004075881A1 (en) 2004-09-10

Family

ID=32922929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000536 WO2004075881A1 (en) 2003-02-28 2004-03-01 Stable pharmaceutical composition of rabeprazole and processes for their preparation

Country Status (3)

Country Link
EP (1) EP1605919A1 (en)
CA (1) CA2517289A1 (en)
WO (1) WO2004075881A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105798A2 (en) * 2005-07-11 2006-10-12 Nycomed Danmark Aps Benzimidazole formulation
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
EP1980244A3 (en) * 2007-04-12 2010-11-17 Nipro Corporation Basis particles and orally-disintegrating tablet containing them
CN105434398A (en) * 2015-12-18 2016-03-30 康普药业股份有限公司 Rabeprazole enteric-coated micro pellet, and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052564A1 (en) * 1997-05-23 1998-11-26 Cipla Limited Benzimidazole pharmaceutical composition and process of preparation
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
EP1004305A1 (en) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
WO2000078293A1 (en) * 1999-06-22 2000-12-28 Astrazeneca Ab New formulation
US20020142034A1 (en) * 1998-05-18 2002-10-03 Toshihiro Shimizu Orally disintegrable tablets

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0995447A1 (en) * 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
WO1998052564A1 (en) * 1997-05-23 1998-11-26 Cipla Limited Benzimidazole pharmaceutical composition and process of preparation
EP1004305A1 (en) * 1998-04-20 2000-05-31 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US20020142034A1 (en) * 1998-05-18 2002-10-03 Toshihiro Shimizu Orally disintegrable tablets
WO2000078293A1 (en) * 1999-06-22 2000-12-28 Astrazeneca Ab New formulation

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105798A2 (en) * 2005-07-11 2006-10-12 Nycomed Danmark Aps Benzimidazole formulation
WO2006105798A3 (en) * 2005-07-11 2006-12-07 Nycomed Danmark Aps Benzimidazole formulation
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
WO2008000463A2 (en) * 2006-06-29 2008-01-03 Lek Pharmaceuticals D.D. Rabeprazole formulation
WO2008000463A3 (en) * 2006-06-29 2008-03-06 Lek Pharmaceuticals Rabeprazole formulation
EP1980244A3 (en) * 2007-04-12 2010-11-17 Nipro Corporation Basis particles and orally-disintegrating tablet containing them
CN105434398A (en) * 2015-12-18 2016-03-30 康普药业股份有限公司 Rabeprazole enteric-coated micro pellet, and preparation method thereof
CN105434398B (en) * 2015-12-18 2018-09-18 康普药业股份有限公司 Species rabeprazole enteric-coated pellets and its preparation method

Also Published As

Publication number Publication date Type
CA2517289A1 (en) 2004-09-10 application
EP1605919A1 (en) 2005-12-21 application

Similar Documents

Publication Publication Date Title
US6428810B1 (en) Pharmaceutical formulation comprising omeprazole
US6749867B2 (en) Delivery system for omeprazole and its salts
US6610323B1 (en) Oral pharmaceutical pulsed release dosage form
US4786505A (en) Pharmaceutical preparation for oral use
US6042847A (en) Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
US6974591B2 (en) Method for producing a controlled-release preparation
US20050095293A1 (en) Administration form for the oral application of poorly soluble drugs
US20050266080A1 (en) Coated tablet formulation and method
US6605303B1 (en) Oral pharmaceutical extended release dosage form
US6013281A (en) Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
US6479075B1 (en) Pharmaceutical formulations for acid labile substances
US6379705B1 (en) Stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles
US20050250838A1 (en) Formulation for sustained delivery
US6210716B1 (en) Controlled release bupropion formulation
US20040028735A1 (en) Pharmaceutical formulation
US6780436B1 (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
US6515010B1 (en) Carvedilol methanesulfonate
US5997903A (en) Oral-administration forms of a medicament containing pantoprazol
US20050042277A1 (en) Pharmaceutical compositions having a swellable coating
US20020098242A1 (en) Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production
US7674479B2 (en) Sustained-release bupropion and bupropion/mecamylamine tablets
US6726927B2 (en) Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
US20050214373A1 (en) Coated tablet formulation and method
US6602522B1 (en) Pharmaceutical formulation for acid-labile compounds
EP0960620A1 (en) A stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2517289

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 3950/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004216405

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004715973

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2004216405

Country of ref document: AU

Date of ref document: 20040301

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004216405

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004715973

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2004715973

Country of ref document: EP